Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

…, M Lakshmanan, P Pais, J Probstfield, FT Botros… - The Lancet, 2019 - thelancet.com
Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes
in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-…

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised …

…, AG Zimmermann, DB Woodward, FT Botros - The lancet Diabetes & …, 2018 - thelancet.com
Background Many antihyperglycaemic drugs, including insulin, are primarily cleared by the
kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long-…

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical …

…, F Giorgino, RT Hietpas, FT Botros - Diabetes/metabolism …, 2016 - Wiley Online Library
Dulaglutide (DU) is a once weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)
approved for the treatment of type 2 diabetes mellitus (T2DM). Glycaemic efficacy and safety …

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study

…, N Galič, HA Ghofrani, G Simonneau, FT Botros… - Journal of the American …, 2012 - jacc.org
Objectives : The aim of this study was to evaluate the long-term safety and durability of
efficacy of tadalafil for pulmonary arterial hypertension. Background : Tadalafil is an oral …

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

…, R Diaz, M Lakshmanan, FT Botros… - The Lancet Diabetes & …, 2020 - thelancet.com
Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1)
receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke …

Collecting duct renin is upregulated in both kidneys of 2-kidney, 1-clip goldblatt hypertensive rats

MC Prieto-Carrasquero, FT Botros, J Pagan… - …, 2008 - Am Heart Assoc
Renin in collecting duct cells is upregulated in chronic angiotensin II–infused rats via angiotensin
II type 1 receptors. To determine whether stimulation of collecting duct renin is a blood …

[HTML][HTML] Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

KC Ferdinand, FT Botros, CM Atisso… - Cardiovascular diabetology, 2016 - Springer
Background Patients with type 2 diabetes (T2D) have a substantial increased risk for
cardiovascular (CV) disease and associated mortality than those without diabetes. Dulaglutide is a …

Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials

…, G Anglin, KD Harper, FT Botros - Diabetes, Obesity …, 2017 - Wiley Online Library
Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the
treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with …

[HTML][HTML] Increase in heme oxygenase-1 levels ameliorates renovascular hypertension

FT Botros, ML Schwartzman, CT Stier Jr, AI Goodman… - Kidney international, 2005 - Elsevier
Increase in heme oxygenase-1 levels ameliorates renovascular hypertension Background
The heme oxygenase system (HO-1 and HO-2) catalyzes the conversion of heme to free iron, …

Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1–7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats

…, RA Gonzįlez-Villalobos, FT Botros… - American Journal …, 2011 - journals.physiology.org
Alterations in the balance between ANG II/ACE and ANG 1–7/ACE2 in ANG II-dependent
hypertension could reduce the generation of ANG 1–7 and contribute further to increased …